NCT05722912

Brief Summary

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 4, 2022

Completed
4 months until next milestone

First Posted

Study publicly available on registry

February 10, 2023

Completed
Last Updated

February 10, 2023

Status Verified

January 1, 2023

First QC Date

October 4, 2022

Last Update Submit

January 26, 2023

Conditions

Graft-versus-host Disease (GVHD)

Keywords

ruxolitinibacute or chronic steroid-refractory GVHDhematopoietic stem cell transplantation (allo-HSCT)

Interventions

RuxolitinibDRUG

Ruxolitinib Cream

Also known as: INCB018424

Sponsors & Collaborators

MeSH Terms

Conditions

Graft vs Host Disease

Interventions

ruxolitinib

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

  • Pooja Khandelwal, MD

    Children's Hospital Medical Center, Cincinnati

    STUDY DIRECTOR

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 4, 2022

First Posted

February 10, 2023

Last Updated

February 10, 2023

Record last verified: 2023-01